AusperBio Secures $63 Million Series B2 Financing to Advance ASO Drug AHB-137 for Chronic Hepatitis B Cure
AusperBio
Biological Vaccine and Nucleic Acid Drug Developer
Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Today, AusperBio: a clinical-stage innovative drug company focused on the independent innovation and development of targeted delivery small nucleic acid drugs with the core goal of "achieving clinical cure for chronic hepatitis B," announced the completion of a US$63 million Series B2 financing round, equivalent to approximately RMB 450 million.
This round of financing was led by Qiming Venture Partners in collaboration with globally renowned industry investment institutions. Multiple top-tier investment firms in China, including Hancorn Capital, CDH VGC, Originn Capital, Sherpa Healthcare Partners, and Origin Capital, also participated. This marks AusperBio's second successful financing round in 2025, bringing the company's total funding for the year to over $1.13 billion.
The funds raised in this round will be mainly invested in the core development areas of AusperBio, focusing on three major directions:
1. Accelerate the clinical trial process of the core product —— AHB-137, an innovative antisense oligonucleotide (ASO) drug for achieving clinical cure of chronic hepatitis B, including the Phase III clinical trial conducted in China, the Phase II clinical trial for combination therapy and treatment-naïve patients, as well as the concurrently advancing overseas Phase II clinical trial;
Secondly, advance the commercialization and industrialization construction of AHB-137 to lay the foundation for its smooth market launch in the future and benefit hepatitis B patients worldwide.
Third, the company will continue to expand its innovative pipeline R&D, strengthen the construction of professional teams both in China and overseas, and accumulate core technologies and talent resources for long-term development.
Dr. Guozheng Cheng, Co-founder and CEO of AusperBio"We are greatly honored to once again receive the trust and support of both new and existing investors. Between 2024 and 2025, AusperBio successfully completed four rounds of financing consecutively. This not only demonstrates the capital market's high recognition of the company’s innovative capabilities but also confirms the commercial potential of AHB-137. Standing at this significant milestone, we will spare no effort to advance the Phase III clinical trial of AHB-137 with high quality and efficiency, while continuing to accelerate the clinical development of multiple innovative oligonucleotide drugs with targeted delivery. Our goal is to meet critical unaddressed medical needs as soon as possible."
Dr. Chengyong Yang, Co-founder and CSO of AusperBioStated: "AHB-137 can efficiently achieve the leap from obtaining Phase I IND approval to Phase III clinical trials, which would not have been possible without the firm support of our investment institutions for the company’s strategy. Previously, clinical data on AHB-137 has been repeatedly presented in breakthrough abstract form at international academic conferences such as EASL and AASLD, drawing widespread attention and in-depth discussion within the academic community. Looking ahead, we will continue to explore more potential of AHB-137 and drive scientific breakthroughs through innovative strategies of combination therapies with multiple mechanisms, leveraging science to advance innovation in the small nucleic acid industry."
Xubo Hu, Managing Partner of Qiming Venture Partners"We are glad to continue our investment and co-lead this round of financing for AusperBio," said the representative. "AusperBio has demonstrated exceptional R&D capabilities and efficient execution, with its core product AHB-137 having successfully entered Phase III clinical trials, showing the potential to become a Best-in-Class therapy. Chronic hepatitis B is a significant global health challenge, and we look forward to the clinical success of AHB-137, which will hopefully bring the gospel of functional cure to patients as soon as possible."
AusperBio, a clinical-stage innovative drug development company operating simultaneously in China and the United States, focuses on developing proprietary targeted delivery small nucleic acid drugs with First-in-class and Best-in-class potential. The company owns the fully proprietary Med-Oligo™ ASO technology platform, primarily concentrating on the functional cure of chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while actively expanding into new target areas beyond the liver. AusperBio’s strategy is to combine its globally leading Med-Oligo™ oligonucleotide technology with a specifically efficient targeted delivery platform to drive the development of a series of innovative therapies, addressing significant unmet medical needs.
AHB-137 is a non-conjugated antisense oligonucleotide (ASO) with the potential to become a cornerstone therapy for the clinical cure of chronic hepatitis B. As the first innovative drug from AusperBio's self-developed Med-Oligo™ platform to enter clinical trials, AHB-137 has demonstrated excellent data in preclinical studies and at several international authoritative academic conferences (including EASL™ 2023–2025, AASLD™ 2024, and APASL™ 2025), garnering widespread attention. Currently, AHB-137 is undergoing Phase III clinical trials in mainland China, Phase II clinical trials for combination therapy and treatment-naïve patients, while simultaneously advancing Phase II clinical trials overseas, accelerating the goal of achieving a clinical cure for hepatitis B through a global strategic layout.
Source: AusperBio
Mastering CAR-T Therapy, Stem Cell Therapy, and Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs